JP5785550B2 - 神経疾患の処置方法 - Google Patents

神経疾患の処置方法 Download PDF

Info

Publication number
JP5785550B2
JP5785550B2 JP2012529062A JP2012529062A JP5785550B2 JP 5785550 B2 JP5785550 B2 JP 5785550B2 JP 2012529062 A JP2012529062 A JP 2012529062A JP 2012529062 A JP2012529062 A JP 2012529062A JP 5785550 B2 JP5785550 B2 JP 5785550B2
Authority
JP
Japan
Prior art keywords
csf
csfr
antibody
human
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012529062A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013504603A5 (enExample
JP2013504603A (ja
Inventor
ブレント スティーブン マッケンジー
ブレント スティーブン マッケンジー
ピーター フレデリック カーウェン
ピーター フレデリック カーウェン
ユージン マラスコフスキ
ユージン マラスコフスキ
Original Assignee
シーエスエル、リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シーエスエル、リミテッド filed Critical シーエスエル、リミテッド
Publication of JP2013504603A publication Critical patent/JP2013504603A/ja
Publication of JP2013504603A5 publication Critical patent/JP2013504603A5/ja
Application granted granted Critical
Publication of JP5785550B2 publication Critical patent/JP5785550B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
JP2012529062A 2009-09-15 2010-09-14 神経疾患の処置方法 Expired - Fee Related JP5785550B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24250309P 2009-09-15 2009-09-15
US61/242,503 2009-09-15
PCT/AU2010/001191 WO2011032204A1 (en) 2009-09-15 2010-09-14 Treatment of neurological conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015109380A Division JP2015187135A (ja) 2009-09-15 2015-05-29 神経疾患の処置方法

Publications (3)

Publication Number Publication Date
JP2013504603A JP2013504603A (ja) 2013-02-07
JP2013504603A5 JP2013504603A5 (enExample) 2013-10-10
JP5785550B2 true JP5785550B2 (ja) 2015-09-30

Family

ID=43757935

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012529062A Expired - Fee Related JP5785550B2 (ja) 2009-09-15 2010-09-14 神経疾患の処置方法
JP2015109380A Pending JP2015187135A (ja) 2009-09-15 2015-05-29 神経疾患の処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015109380A Pending JP2015187135A (ja) 2009-09-15 2015-05-29 神経疾患の処置方法

Country Status (11)

Country Link
US (2) US9364534B2 (enExample)
EP (1) EP2477656B1 (enExample)
JP (2) JP5785550B2 (enExample)
KR (1) KR101750426B1 (enExample)
CN (1) CN102630167B (enExample)
AU (1) AU2010295223B2 (enExample)
CA (1) CA2773552C (enExample)
DK (1) DK2477656T3 (enExample)
ES (1) ES2623802T3 (enExample)
PL (1) PL2477656T3 (enExample)
WO (1) WO2011032204A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110117092A1 (en) * 2009-10-20 2011-05-19 The Regents Of The University Of Michigan Compositions and methods for inhibiting g-csfr
RU2605595C2 (ru) 2011-06-13 2016-12-20 СиЭсЭл Лимитид Антитела против g-csfr и их применение
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
US20210179721A1 (en) 2017-11-29 2021-06-17 Csl Limited Method of treating or preventing ischemia-reperfusion injury
US12281160B2 (en) 2018-03-23 2025-04-22 Csl Limited Method of treating asthma
WO2019226550A1 (en) * 2018-05-21 2019-11-28 CHS Pharma Inc. Granulocyte colony-stimulating factor (gcsf) gene therapy for treating neurological diseases
BR112021010920A2 (pt) * 2018-12-04 2021-08-31 CSL Innovation Pty Ltd Método de tratamento de condições neutrofílicas
EP4739706A1 (en) 2023-07-05 2026-05-13 CSL Innovation Pty Ltd Methods of treating or preventing a complication of sickle cell disease
WO2025217678A1 (en) * 2024-04-15 2025-10-23 CSL Innovation Pty Ltd Methods of treating or delaying progression or hindering development of a neutrophil-associated condition

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IE66494B1 (en) 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
WO1997042224A1 (en) * 1996-05-07 1997-11-13 Millennium Biotherapeutics, Inc. Neurotactin and uses therefor
EP1261337B1 (en) * 2000-02-28 2008-09-10 The University Of British Columbia Topoisomerase inhibitors for treatment of surgical adhesions
US7108852B2 (en) * 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
WO2002078643A2 (en) * 2001-03-30 2002-10-10 Philadelphia Health And Education Corporation Immunomodulation and effect on cell processes relating to serotonin family receptors
US20060093604A1 (en) * 2002-08-23 2006-05-04 The Walter And Eliza Hall Institute Of Medical Research Method of treatment and prophylaxis
AU2004244626A1 (en) * 2003-05-23 2004-12-09 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
WO2005121174A2 (en) * 2004-06-04 2005-12-22 Five Prime Therapeutics, Inc. Novel g-csf polypeptides, polynucleotides, modulators thereof, and methods of use
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2654894A1 (en) 2006-07-06 2008-10-01 Laboratoires Serono S.A. Csf3r polypeptides and uses thereof
AU2007283463B2 (en) 2006-08-11 2012-04-26 Csl Limited Treatment of pulmonary disease conditions
WO2008125903A2 (en) * 2006-12-12 2008-10-23 Chaim Sheba Medical Center Method of inhibiting an undesired immune response

Also Published As

Publication number Publication date
KR101750426B1 (ko) 2017-06-23
CN102630167B (zh) 2015-06-10
US9352038B2 (en) 2016-05-31
JP2013504603A (ja) 2013-02-07
EP2477656A4 (en) 2013-07-03
ES2623802T3 (es) 2017-07-12
KR20120091057A (ko) 2012-08-17
AU2010295223A1 (en) 2012-03-29
JP2015187135A (ja) 2015-10-29
AU2010295223B2 (en) 2015-05-07
CA2773552C (en) 2017-11-21
DK2477656T3 (en) 2017-06-26
PL2477656T3 (pl) 2017-09-29
EP2477656B1 (en) 2017-03-29
US20140234303A1 (en) 2014-08-21
US20110091456A1 (en) 2011-04-21
WO2011032204A1 (en) 2011-03-24
US9364534B2 (en) 2016-06-14
CN102630167A (zh) 2012-08-08
CA2773552A1 (en) 2011-03-24
EP2477656A1 (en) 2012-07-25

Similar Documents

Publication Publication Date Title
JP2015187135A (ja) 神経疾患の処置方法
JP5235881B2 (ja) 肺疾患病態の処理
KR101800467B1 (ko) 루푸스 치료 방법 및 조성물
KR20170072928A (ko) 조합물
AU2020350715A1 (en) GIPR antibody and fusion protein between same and GLP-1, and pharmaceutical composition and application thereof
CN104470541A (zh) 用于治疗涉及运动神经元的疾患的lingo-2拮抗剂
EP4490187A2 (en) Epo receptor agonists and antagonists
US8968731B2 (en) Treatment of uveitis
WO2023020624A1 (en) Use of alpha-enolase antagonist in treating fibrotic diseases
US7740856B2 (en) Effect of BST2 on inflammation
CN117751141A (zh) 用于预防或治疗癌症的抗cd300c单克隆抗体及其生物标志物
AU2012201934A1 (en) Treatment of Pulmonary disease conditions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130819

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150529

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150619

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150708

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150724

R150 Certificate of patent or registration of utility model

Ref document number: 5785550

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees